ArticleApplied biochemistry and biotechnology2026
miR-155-3p in Systemic Lupus Erythematosus: Association with Immune Activation and Renal-Related Parameters.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune illness that affects multiple organs, causes hematological abnormalities, and alters immunological regulation. Identifying reliable biomarkers is critical for improving the diagnosis and monitoring of disease activity. This study aimed to evaluate clinical, biochemical, immunological, and molecular alterations in SLE patients compared with healthy controls, with a focus on the exploratory discrimination of whole-blood miRNA expression and conventional serological markers. A total of 100 SLE patients and 50 age-and gender-matched healthy controls were evaluated. Hematological, biochemical, and immunological markers were examined with miR-21-5p and miR-155-3p expression. Clinical relevance was determined using correlation analyses and ROC curve evaluations. SLE patients had significantly lower hemoglobin, WBCs, and platelets compared to controls (p < 0.001). Inflammatory indicators, such as CRP and ESR, were significantly higher (p < 0.001). Immunological testing showed significant increases in ANA, anti-dsDNA, and anti-Smith antibodies, as well as decreased complement (C3, C4) levels (all p < 0.001). miR-155-3p was considerably elevated in SLE patients and linked with anti-Smith antibodies and creatinine (p < 0.05), but miR-21-5p had no diagnostic significance. ROC analysis showed excellent diagnostic performance for ANA (AUC = 0.992) and anti-dsDNA (AUC = 0.973), with good accuracy for miR-155-3p (AUC = 0.813, p < 0.001). SLE patients have significant hematological, immunological, and renal changes. Among molecular indicators, miR-155-3p is associated with immune activation and selected renal-related laboratory parameters, including serum creatinine, without implying definitive renal involvement, indicating its potential as a complementary biomarker. These findings suggest that miR-155-3p may serve as an exploratory complementary biomarker alongside conventional serological markers; however, its incremental diagnostic value requires validation using multivariable diagnostic models in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.